Mysterious molecular phenomenon could boost precision of targeted drug delivery
Scientists have shown how a type of cellular binding could help pave the way for highly targeted therapies against diseases like cancer.
Faulty genes and misguided antibodies underlie life-threatening COVID-19
New research has shed light on why some people develop a more severe form of COVID-19 than others.
Feature
“It’s been devastating”: How COVID-19 is impacting Alzheimer’s research and care
Alzheimer’s researcher Dr Ashwin Venkataraman shares first-hand insights into how the COVID-19 pandemic has affected patients and ongoing research.
Potential therapeutic targets for cancer-causing virus uncovered by new research
Scientists have discovered key factors that control the genome maintenance and replication of a virus responsible for a rare form of cancer.
Studying coronavirus transmission in children could help cut COVID spread
Imperial researchers are set to begin a study exploring how the virus causing COVID-19 is transmitted by children.
Feature
T cell immunity: What is it and how does it help to protect us from COVID-19?
Over the past few months, you’ll have heard a lot about the importance of antibodies and how they can help us to understand our immunity to COVID-19.
12
Imperial White City Incubator companies pivot in response to COVID-19
Companies at Imperial’s startup incubator are adapting their technology and applying their skillsets to help the fight against the pandemic.
Feature
Imperial’s expertise to help companies to shape the ‘new normal’
Imperial’s world-leading academics have been prominent in responding to COVID-19. As lockdowns eases, they’re helping shape our long-term adaptation.
Professor José Penadés appointed as new Director of the MRC CMBI
Professor José Penadés has been appointed as Director of the MRC Centre for Molecular Bacteriology and Infection (CMBI), commencing 1 July 2020.
Video
Imperial’s COVID-19 vaccine trial: how will it work?
Dr Hannah Cheeseman breaks down some of the key questions surrounding Imperial's COVID-19 vaccine study, which launched last week.
4
